CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...
View CRISPR Therapeutics AG CRSP stock quote prices, financial information, real-time forecasts, and company news from CNN.
The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.
CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech company, achieved a major milestone when it earned approval for the first CRISPR-based medicine in 2023. However, the company has significantly ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...
Looking ahead to 2030, our model projects CRSP could trade at an average price of $204.19, with a potential range between $153.14 and $255.23. This represents a potential 281.3% return from today's ...
It has also aggressively invested in gene editing, including its 2025 acquisition of cardiovascular disease gene-editing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results